Caprius of Fort Lee, NJ, completed its exit from the medical imaging field by acquiring an in vitro diagnostics company in late June. Caprius announced that it had acquired Opus Diagnostics and intends to market a line of therapeutic drug monitoring
Caprius of Fort Lee, NJ, completed its exit from the medical imaging field by acquiring an in vitro diagnostics company in late June. Caprius announced that it had acquired Opus Diagnostics and intends to market a line of therapeutic drug monitoring products. Caprius previously marketed the Aurora breast MRI scanner until it sold that business in April to Pacific Republic Capital of Newport Beach, CA (SCAN 5/12/99). As part of the deal, several Opus executives have been appointed to lead Caprius. Caprius long-time chairman and CEO, Jack Nelson, will be leaving the company, as will president Enrique Levy.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.